Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 776

1.

Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia.

Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, Salerno JU, Igidbashian D, Raviele A, Disertori M, Zanotto G, Verlato R, Vergara G, Delise P, Turrini P, Basso C, Naccarella F, Maddalena F, Estes NA 3rd, Buja G, Thiene G.

Circulation. 2003 Dec 23;108(25):3084-91. Epub 2003 Nov 24.

2.

Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia.

Corrado D, Calkins H, Link MS, Leoni L, Favale S, Bevilacqua M, Basso C, Ward D, Boriani G, Ricci R, Piccini JP, Dalal D, Santini M, Buja G, Iliceto S, Estes NA 3rd, Wichter T, McKenna WJ, Thiene G, Marcus FI.

Circulation. 2010 Sep 21;122(12):1144-52. doi: 10.1161/CIRCULATIONAHA.109.913871. Epub 2010 Sep 7.

3.

Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients.

Wichter T, Paul M, Wollmann C, Acil T, Gerdes P, Ashraf O, Tjan TD, Soeparwata R, Block M, Borggrefe M, Scheld HH, Breithardt G, Böcker D.

Circulation. 2004 Mar 30;109(12):1503-8. Epub 2004 Mar 8.

4.

Ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy: clinical presentation, risk stratification and results of long-term follow-up.

Pezawas T, Stix G, Kastner J, Schneider B, Wolzt M, Schmidinger H.

Int J Cardiol. 2006 Mar 8;107(3):360-8.

PMID:
16503259
5.

Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention.

Bhonsale A, James CA, Tichnell C, Murray B, Gagarin D, Philips B, Dalal D, Tedford R, Russell SD, Abraham T, Tandri H, Judge DP, Calkins H.

J Am Coll Cardiol. 2011 Sep 27;58(14):1485-96. doi: 10.1016/j.jacc.2011.06.043.

6.
7.
8.

Implantable cardioverter-defibrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy.

Roguin A, Bomma CS, Nasir K, Tandri H, Tichnell C, James C, Rutberg J, Crosson J, Spevak PJ, Berger RD, Halperin HR, Calkins H.

J Am Coll Cardiol. 2004 May 19;43(10):1843-52.

9.

Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD?

Wichter T, Paul TM, Eckardt L, Gerdes P, Kirchhof P, Böcker D, Breithardt G.

Herz. 2005 Mar;30(2):91-101. Review.

PMID:
15875097
10.

Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy.

Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ.

J Am Coll Cardiol. 1999 May;33(6):1596-601.

11.

Clinical study of 39 Chinese patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy.

Ma KJ, Li N, Wang HT, Chu JM, Fang PH, Yao Y, Ma J, Hua W, Zhang S, Wang FZ, Li Z, Pu JL.

Chin Med J (Engl). 2009 May 20;122(10):1133-8.

PMID:
19493458
12.

Long term results of cardioverter-defibrillator implantation in patients with right ventricular dysplasia and malignant ventricular tachyarrhythmias.

Tavernier R, Gevaert S, De Sutter J, De Clercq A, Rottiers H, Jordaens L, Fonteyne W.

Heart. 2001 Jan;85(1):53-6.

13.

Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.

Vieira AP, Adragão PP, Santos KR, Morgado FB, Cavaco DM, Rossi R, Abecasis M, Neves JP, Bonhosrst D, Gomes JL, Gomes RS.

Rev Port Cardiol. 2005 Mar;24(3):407-15. English, Portuguese.

PMID:
15929624
14.

Arrhythmogenic right ventricular dysplasia: a United States experience.

Dalal D, Nasir K, Bomma C, Prakasa K, Tandri H, Piccini J, Roguin A, Tichnell C, James C, Russell SD, Judge DP, Abraham T, Spevak PJ, Bluemke DA, Calkins H.

Circulation. 2005 Dec 20;112(25):3823-32. Epub 2005 Dec 12.

15.

[The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].

Marín F, Gimeno JR, Payá E, García-Alberola A, Pérez-Alvarez L, Fernández X, de la Morena G, Sogorb F, Castro-Beiras A, Valdés M, Martínez JG, Monserrat L.

Rev Esp Cardiol. 2006 Jun;59(6):537-44. Spanish.

16.

Long-term follow-up in patients with arrhythmogenic right ventricular cardiomyopathy.

Li CH, Lin YJ, Huang JL, Wu TJ, Cheng CC, Lin WS, Tuan TC, Chang SL, Lo LW, Hu YF, Chao TF, Chung FP, Tsai CF, Tsao HM, Chen SA.

J Cardiovasc Electrophysiol. 2012 Jul;23(7):750-6. doi: 10.1111/j.1540-8167.2011.02288.x. Epub 2012 Feb 21.

PMID:
22353378
17.

Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.

Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, Bardy GH, Favale S, Rea RF, Boriani G, Estes NA 3rd, Spirito P.

N Engl J Med. 2000 Feb 10;342(6):365-73.

18.

Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy.

Begley DA, Mohiddin SA, Tripodi D, Winkler JB, Fananapazir L.

Pacing Clin Electrophysiol. 2003 Sep;26(9):1887-96.

PMID:
12930505
20.

Sudden death in implantable cardioverter-defibrillator recipients: clinical context, arrhythmic events and device responses.

Pires LA, Lehmann MH, Steinman RT, Baga JJ, Schuger CD.

J Am Coll Cardiol. 1999 Jan;33(1):24-32.

Supplemental Content

Support Center